NeuroMab™ Anti-SOD1 Antibody(NRP-0422-P647)

Figure 1 Binding specificity of human antibody to human recombinant SOD1.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates in PDAPP mouse brain tissue. IgG is used as a negative control in this experiment because it cannot bind Aβ and therefore cannot induce phagocytosis.

Figure 3 Antibodies preferentially bind misfolded/aggregated human SOD1.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates in PDAPP mouse brain tissue. IgG is used as a negative control in this experiment because it cannot bind Aβ and therefore cannot induce phagocytosis.

Figure 2 Binding specificity of human antibody to human recombinant SOD1.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates in PDAPP mouse brain tissue. IgG is used as a negative control in this experiment because it cannot bind Aβ and therefore cannot induce phagocytosis.

Figure 4 NI-204.10D12 mainly showed SOD1 pathology and diffuse staining of scattered inclusions in the cells.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates in PDAPP mouse brain tissue. IgG is used as a negative control in this experiment because it cannot bind Aβ and therefore cannot induce phagocytosis.

Figure 5 NI-204.10D12 treatment prevents motor neuron degeneration mediated by mutant SOD-1 overexpression.

h3D6v2 was as effective as chimeric 3D6 in inducing phagocytosis of Aβ aggregates in PDAPP mouse brain tissue. IgG is used as a negative control in this experiment because it cannot bind Aβ and therefore cannot induce phagocytosis.